We are live on ! Find out more
DC

Davenport & Co Portfolio holdings

AUM $20.4B
1-Year Est. Return 18.11%
This Fund
S&P 500
This Quarter Est. Return
-0.27%
1 Year Est. Return
+18.11%
3 Year Est. Return
+63.26%
5 Year Est. Return
+74.4%
10 Year Est. Return
+287.26%
AUM
$16.6B
AUM Growth
+$247M
Cap. Flow
+$503M
Cap. Flow %
3.04%
Top 10 Hldgs %
19.53%
Holding
1,181
New
73
Increased
547
Reduced
415
Closed
69

Top Buys

Rank Stock Value
1
AMT icon
American Tower
AMT
+$78.6M
2
PEP icon
PepsiCo
PEP
+$71.4M
3
AAPL icon
Apple
AAPL
+$64.4M
4
HSY icon
Hershey
HSY
+$57.7M
5
ADBE icon
Adobe
ADBE
+$49.1M

Top Sells

Rank Stock Value
1
INTU icon
Intuit
INTU
+$108M
2
HON icon
Honeywell
HON
+$72.9M
3
ALL icon
Allstate
ALL
+$66.1M
4
AVY icon
Avery Dennison
AVY
+$62.4M
5
CB icon
Chubb
CB
+$55.5M

Sector Composition

Rank Sector Weight
1 Technology 15.55%
2 Financials 15.26%
3 Healthcare 11.12%
4 Consumer Discretionary 9.61%
5 Industrials 9.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SWN
1101
DELISTED
Southwestern Energy Company
SWN
$74K ﹤0.01%
11,000
ESPR
1102
DELISTED
Esperion Therapeutics
ESPR
$66.6K ﹤0.01%
+30,000
New +$70.6K
OPAL icon
1103
OPAL Fuels
OPAL
$62.5M
$65.4K ﹤0.01%
16,000
+2,100
+15% +$9.87K
IAF
1104
abrdn Australia Equity Fund
IAF
$122M
$63.9K ﹤0.01%
+4,921
New +$63.3K
EGHT icon
1105
8x8 Inc
EGHT
$279M
$44.6K ﹤0.01%
20,082
-10,000
-33% -$24.3K
BRBS icon
1106
Blue Ridge Bankshares
BRBS
$313M
$35.6K ﹤0.01%
13,639
+3,026
+29% +$8.44K
BTAI icon
1107
BioXcel Therapeutics
BTAI
$24.8M
$27.1K ﹤0.01%
1,325
-824
-38% -$27.6K
MAXN
1108
DELISTED
Maxeon Solar Technologies
MAXN
$11.9K ﹤0.01%
140
SGMO
1109
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4.84K ﹤0.01%
13,500
CELG.RT
1110
Bristol-Myers Squibb Rights
CELG.RT
$165M
$3.44K ﹤0.01%
83,970
HOFVW
1111
DELISTED
Hall of Fame Resort & Entertainment Company Warrant
HOFVW
$114 ﹤0.01%
10,333
-3,000
-23% -$29
ALIT icon
1112
CALL
Alight
ALIT
$534M
-2,500
Closed -$493K
AMZN icon
1113
CALL
Amazon
AMZN
$2.44T
-1,300
Closed -$234K
AXSM icon
1114
Axsome Therapeutics
AXSM
$11.7B
-5,817
Closed -$464K
BBY icon
1115
Best Buy
BBY
$19B
-2,798
Closed -$230K
BMO icon
1116
Bank of Montreal
BMO
$123B
-2,108
Closed -$206K
BWXT icon
1117
BWX Technologies
BWXT
$14.4B
-1,975
Closed -$203K
CHE icon
1118
Chemed
CHE
$7.16B
-431
Closed -$277K
CHTR icon
1119
Charter Communications
CHTR
$17.3B
-55,917
Closed -$16.3M
CIK
1120
Credit Suisse Asset Management Income Fund
CIK
$134M
-14,500
Closed -$42.8K
CLF icon
1121
Cleveland-Cliffs
CLF
$6.49B
-20,953
Closed -$476K
DHIL
1122
DELISTED
Diamond Hill
DHIL
-91,988
Closed -$14.1M
EDOW icon
1123
First Trust Dow 30 Equal Weight ETF
EDOW
$313M
-18,293
Closed -$630K
EQIX icon
1124
Equinix
EQIX
$99.4B
-307
Closed -$253K
ERIC icon
1125
Ericsson
ERIC
$32.1B
-16,037
Closed -$88.4K

Similar funds

Davenport & Co's Q2 2024 Portfolio in Review

As of Q2 2024, Davenport & Co held 1,181 positions worth $16.6B, up 1.5% from $16.3B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Davenport & Co deployed $503M of net new capital in Q2 2024, opening 73 new positions and adding to 547 existing holdings. Its largest new stake was Golden Entertainment: 467,594 shares worth $14.5M.

By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 15% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was Intuit, an estimated $108M trimmed.

  • Davenport & Co's largest Q2 2024 buy was Golden Entertainment: 467,594 shares worth $14.5M.
  • Davenport & Co added most to American Tower in Q2 2024, an estimated $78.6M increase.
  • Davenport & Co's biggest Q2 2024 reduction was Intuit, cutting an estimated $108M.
  • Davenport & Co fully exited Vestis in Q2 2024, selling an estimated $21.7M.
  • Davenport & Co's ten largest holdings make up 20% of its $16.6B portfolio in Q2 2024.
  • Davenport & Co opened 73 new positions and closed 69 in Q2 2024.
  • Davenport & Co's portfolio value rose 1.5% quarter-over-quarter to $16.6B.

Based on Davenport & Co's 13F filing for Q2 2024, filed 6 Aug 2024.